NOTCH3 p.Arg1231Cys is markedly enriched in South Asians and associated with stroke
- PMID: 39271666
- PMCID: PMC11399414
- DOI: 10.1038/s41467-024-51819-3
NOTCH3 p.Arg1231Cys is markedly enriched in South Asians and associated with stroke
Abstract
The genetic factors of stroke in South Asians are largely unexplored. Exome-wide sequencing and association analysis (ExWAS) in 75 K Pakistanis identified NM_000435.3(NOTCH3):c.3691 C > T, encoding the missense amino acid substitution p.Arg1231Cys, enriched in South Asians (alternate allele frequency = 0.58% compared to 0.019% in Western Europeans), and associated with subcortical hemorrhagic stroke [odds ratio (OR) = 3.39, 95% confidence interval (CI) = [2.26, 5.10], p = 3.87 × 10-9), and all strokes (OR [CI] = 2.30 [1.77, 3.01], p = 7.79 × 10-10). NOTCH3 p.Arg231Cys was strongly associated with white matter hyperintensity on MRI in United Kingdom Biobank (UKB) participants (effect [95% CI] in SD units = 1.1 [0.61, 1.5], p = 3.0 × 10-6). The variant is attributable for approximately 2.0% of hemorrhagic strokes and 1.1% of all strokes in South Asians. These findings highlight the value of diversity in genetic studies and have major implications for genomic medicine and therapeutic development in South Asian populations.
© 2024. The Author(s).
Conflict of interest statement
The authors declare the following competing interests. Funding. Fieldwork for this study was funded by the Center for Non-Communicable Diseases, Pakistan. DNA sequencing was funded by Regeneron Pharmaceuticals Inc. Employment. J.L.R.F., A.R.S., N.B., D.eS., M.C., J.O., J.R., B.Y., M.K., J.B., G.T., S.G., T.D., N.V., L.A.L., A.Z., N.P., F.S., J.M., G.C., P.X., A.B., S.A.D.G., H.M., I.T., K.K., A.E., D.D.A., S.F., W.L., T.C. and R.G.C. consortium members are or were employees of Regeneron Genetics Center L.L.C. or Regeneron Pharmaceuticals Inc. and contributed to this manuscript as part of their regular duties as salaried employees. E.T. and S.C. are or were student interns of Regeneron Genetics Center LLC or Regeneron Pharmaceuticals Inc. and contributed to this manuscript as part of their internship activites. A.R., M.J., M.Z., M.R.M., M.B.L., P.F., and D.S. and S.K. are or were employees of the Center for Non-Communicable Disease and received salaried compensation for their contribution to this manuscript. Personal Financial Interests. J.L.R.F., A.R.S., N.B., D.eS., M.C., J.O., J.R., B.Y., M.K., J.B., G.T., S.G., T.D., N.V., L.A.L., A.Z., N.P., F.S., J.M., G.C., P.X., A.B., S.A.D.G., H.M., I.T., K.K., A.E., D.D.A., S.F., W.L., T.C., and R.G.C. consortium members are or were employees of Regeneron Genetics Center L.LC. or Regeneron Pharmaceuticals Inc. and received stock and stock options as part of their compensation as employees. J.L.R.F., A.R.S., D.S., A.B., and S.K. are named inventors on patent pending US 20230000897A1 that discloses methods of treating subjects having a cerebrovascular disease by administering Neurogenic Locus Notch Homolog Protein 3 (
Figures



References
-
- Valcarcel-Nazco, C. et al. Variability in the use of neuroimaging techniques for diagnosis and follow-up of stroke patients. Neurologia (Engl. Ed.)34, 360–366 (2019). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous